Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of liver diseases, primarily non-alcoholic steatohepatitis (NASH) and related conditions
The company’s lead product candidate aims to address the unmet medical needs of patients suffering from these chronic diseases by targeting the underlying mechanisms of liver damage and fibrosis. Through innovative research and development, Galmed is committed to advancing its pipeline of therapeutic solutions to improve patient outcomes and contribute to the evolving landscape of liver disease management.
Stocks got a boost as the Federal Reserve cut interest rates, but investors should expect more volatility as economic data continues to deliver mixed signals
PALM BEACH, Fla., Sept. 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer cells removed during the biopsy are examined to check the presence of progesterone or estrogen receptor proteins. The hormones, i.e. estrogen and progesterone, encourage cancer growth when they bind to these receptors. If these receptors are present, cancers are classified as hormone receptor-positive or hormone receptor-negative (proteins). Breast cancer develops due to reasons, such as BRCA gene mutation and PIK3CA gene mutation etc. Ducts and lobules are the major components of a breast, and everything is held together by the connective tissue which surrounds it. Breast cancer develops where the ducts or lobules are located, and it can spread to other body parts via blood and lymph arteries. Breast cancer is metastasized when it spreads to other body regions. Advanced breast cancer is another word for metastatic breast cancer. Advanced breast cancer is defined in medical terms as breast cancer that has gone beyond the breast to other essential organs in the body, such as the bones, lungs, liver, or brain, to mention a few. Metastatic breast cancer usually develops months or years after a person has finished treatment for an early or locally advanced variety of breast cancer, such as stage I, II, or III. As a result, metastatic breast cancer is also known as distant recurrence. A report from Strategic Market Research predicted that the global metastatic breast cancer treatment market is expected to expand at a CAGR of 10.4% to reach $41.74 billion by 2030 during the period 2021-2030. The report said: “The most commonly prescribed treatments for metastatic breast cancer are chemotherapy and radiation therapy. Both of these treatments help to slow tumor growth. On the other hand, hormone therapy is the most successful treatment since it helps to limit the growth of cancer cells. The metastatic breast cancer treatment market trends like the introduction of more advanced technologies and rising demand for metastatic breast cancer therapies are some of the primary drivers driving the global market's growth.” Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQONCY) (TSX: ONC), Novartis AG NYSE: NVSNYSENVS)(NYSE: MRKNYSEMRK, Pfizer Inc. (NYSE: PFENYSE), Galmed Pharmaceuticals Ltd. (NASDAQ: GLMDGLMD).
Galmed Pharmaceuticals Ltd (NASDAQGLMD) shares are surging Thursday after the company announced plans to broaden its drug development activities over the next two years.
Shares of PriceSmart, Inc. (NASDAQPSMT) rose sharply in today’s pre-market trading as the company posted better-than-expected earnings for its second quarter.
Shares of Agenus Inc. (NASDAQAGEN) fell sharply during Monday’s session. Agenus disclosed a 1-for-20 reverse stock split of common stock. Agenus Inc. NASDAQ: AGENNASDAQAGEN)
Shares of Esperion Therapeutics, Inc. (NASDAQESPR) shares rose sharply during today’s pre-market trading after the company presented new data from CLEAR outcomes at ACC.24 highlighting value of NEXLETOL® tablets in diverse populations.
